924 related articles for article (PubMed ID: 18343273)
41. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland.
Tilson L; Usher C; Butler K; Fitzsimons J; O'Hare F; Cotter S; O'Flanagan D; Johnson H; Barry M
Value Health; 2008; 11(5):898-903. PubMed ID: 18489504
[TBL] [Abstract][Full Text] [Related]
42. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
[TBL] [Abstract][Full Text] [Related]
43. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).
Beutels P; Thiry N; Van Damme P
Vaccine; 2007 Feb; 25(8):1355-67. PubMed ID: 17208339
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy.
Giorgi-Rossi P; Merito M; Borgia P
Health Policy; 2009 Feb; 89(2):225-38. PubMed ID: 18639952
[TBL] [Abstract][Full Text] [Related]
45. Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations.
Snedecor SJ; Strutton DR; Ciuryla V; Schwartz EJ; Botteman MF
Vaccine; 2009 Jul; 27(34):4694-703. PubMed ID: 19520197
[TBL] [Abstract][Full Text] [Related]
46. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
Giglio N; Micone P; Gentile A
Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
[TBL] [Abstract][Full Text] [Related]
47. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review.
Myint TT; Madhava H; Balmer P; Christopoulou D; Attal S; Menegas D; Sprenger R; Bonnet E
Adv Ther; 2013 Feb; 30(2):127-51. PubMed ID: 23397399
[TBL] [Abstract][Full Text] [Related]
48. Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong.
Lee KK; Rinaldi F; Chan MK; Chan ST; So TM; Hon EK; Lee VW
Value Health; 2009; 12 Suppl 3():S42-8. PubMed ID: 20586981
[TBL] [Abstract][Full Text] [Related]
49. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.
Albrich WC; Baughman W; Schmotzer B; Farley MM
Clin Infect Dis; 2007 Jun; 44(12):1569-76. PubMed ID: 17516400
[TBL] [Abstract][Full Text] [Related]
50. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines.
Chuck AW; Jacobs P; Tyrrell G; Kellner JD
Vaccine; 2010 Jul; 28(33):5485-90. PubMed ID: 20554066
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
Marchetti M; Colombo GL
Vaccine; 2005 Aug; 23(37):4565-76. PubMed ID: 15992969
[TBL] [Abstract][Full Text] [Related]
53. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness.
Fedson DS
Semin Respir Infect; 1993 Dec; 8(4):285-93. PubMed ID: 7938925
[TBL] [Abstract][Full Text] [Related]
54. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.
Armstrong GL; Billah K; Rein DB; Hicks KA; Wirth KE; Bell BP
Pediatrics; 2007 Jan; 119(1):e22-9. PubMed ID: 17200247
[TBL] [Abstract][Full Text] [Related]
55. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
[TBL] [Abstract][Full Text] [Related]
56. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
[TBL] [Abstract][Full Text] [Related]
57. Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly.
van Werkhoven CH; Hollingsworth RC; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Sanders EA; Bonten MJ
Vaccine; 2016 Jun; 34(28):3275-82. PubMed ID: 27171754
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study.
Barricarte A; Castilla J; Gil-Setas A; Torroba L; Navarro-Alonso JA; Irisarri F; Arriazu M
Clin Infect Dis; 2007 Jun; 44(11):1436-41. PubMed ID: 17479939
[TBL] [Abstract][Full Text] [Related]
59. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.
Kawakami K; Ohkusa Y; Kuroki R; Tanaka T; Koyama K; Harada Y; Iwanaga K; Yamaryo T; Oishi K
Vaccine; 2010 Oct; 28(43):7063-9. PubMed ID: 20723631
[TBL] [Abstract][Full Text] [Related]
60. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales.
Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
Clin Infect Dis; 2013 Mar; 56(5):633-40. PubMed ID: 23175560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
